Molecular regulatory network of glycolytic reprogramming in hepatocellular carcinoma and its clinical implications Authors: Hengzhou Zhu, Jiahui Li, Jiaying Zhang, Dong Niu, Weiwang Zheng, Chunhui Jin Published: 2025 ABSTRACT AbstractHepatocellular carcinoma (HCC) ranks among the most prevalent malignant tumors worldwide, exhibiting persistently high incidence and mortality rates. Metabolic reprogramming, particularly the ‘Warburg effect’ characterized by aberrantly enhanced glycolysis, serves as a hallmark feature of HCC and various other malignancies. Even under oxygen-sufficient conditions, tumor cells preferentially utilize the glycolytic pathway to convert glucose into lactate. This metabolic mode not only supplies essential energy (ATP) for rapid tumor cell proliferation but, more critically, provides key intermediate metabolites for synthesizing macromolecules such as nucleic acids, lipids, and amino acids. It concurrently regulates the pH and redox status of the tumor microenvironment, thereby robustly supporting tumor growth, invasion, and metastasis. Recent years have witnessed significant advances in research on glycolytic regulatory mechanisms in HCC, revealing an exceptionally complex regulatory network composed of diverse molecules and signaling pathways. This review aims to systematically organize and elucidate the multi-layered molecular mechanisms regulating glycolytic reprogramming in HCC. We will comprehensively examine the multidimensional regulation of key enzymes and glucose transporters within the glycolytic pathway, encompassing transcriptional control, post-translational modifications, and other regulatory layers; We will conduct an in-depth analysis of the central role played by non-coding RNAs (ncRNAs)—including long non-coding RNAs (lncRNAs), circular RNAs (circRNAs), and microRNAs (miRNAs)—within the glycolytic regulatory network of HCC; Elucidate how classical signaling pathways and key transcription factors synergistically interact to precisely regulate the glycolytic process; Analyze how post-translational modifications fine-tune the activity of glycolytic enzymes; And discuss how various components within the tumor microenvironment and intercellular communication mechanisms reshape the metabolic phenotypes of HCC. Furthermore, this review summarizes the clinical application value of positron emission tomography (PET) technology based on glycolytic activity in the diagnosis, staging, and prognostic evaluation of HCC. Through a comprehensive elucidation of these complex regulatory networks, this work aims to enhance comprehension of HCC metabolic characteristics and provide a theoretical foundation for exploring novel therapeutic targets and clinical strategies.Keywords: Hepatocellular carcinoma, Glycolysis, Metabolic reprogramming, Warburg effect, Molecular regulatory network, Tumor microenvironment, Biomarkers Introduction Hepatocellular carcinoma (HCC) represents the predominant pathological type of primary liver cancer, accounting for approximately 90% of all liver cancer cases, and stands as one of the leading causes of cancer-related mortality worldwide [1]. Despite certain advancements in diagnosis and treatment, the overall prognosis for HCC patients remains poor due to its insidious onset, rapid progression, and high propensity for recurrence and metastasis. Consequently, elucidating the molecular mechanisms underlying HCC pathogenesis and progression, along with identifying effective therapeutic targets and prognostic biomarkers, constitutes an urgent scientific challenge in current liver cancer research. In the 1920s, Otto Warburg first observed the unique metabolic pattern of tumor cells: even under aerobic conditions, they preferentially obtain energy through glycolysis rather than the more efficient mitochondrial oxidative phosphorylation [2]. This phenomenon was termed the ‘Warburg effect’ or aerobic glycolysis. Initially, this metabolic shift was thought to result from impaired mitochondrial function [3]. However, as research advanced, it has been recognized that this represents an actively regulated, precisely controlled adaptive process; it stands as one of the most critical hallmark characteristics of tumor cells. For highly proliferative tumor cells, rapid glycolysis not only generates ATP swiftly to meet energy demands but more crucially, key intermediates like Glucose-6-phosphate, Fructose-6-phosphate, and glyceraldehyde-3-phosphate can be diverted into the pentose phosphate pathway (PPP), hexosamine biosynthesis pathway, and serine synthesis pathway. This metabolic shunting provides essential precursors for nucleotide, lipid, non-essential amino acid, and reduced nicotinamide adenine dinucleotide phosphate (NADPH) biosynthesis, thereby supporting cellular anabolic requirements and maintaining redox homeostasis [4]. Moreover, lactate—the end product of glycolysis—accumulates abundantly and is secreted extracellularly, leading to acidification of the tumor microenvironment. This not only promotes tumor invasion and metastasis but also suppresses immune cell function, facilitating tumor immune escape [5, 6]. The occurrence and development of HCC are also closely linked to profound metabolic reprogramming, in which aberrant activation of glycolysis plays a central role [7]. Numerous studies demonstrate that expression levels of multiple key enzymes in the glycolytic pathway and glucose transporters are significantly upregulated in HCC tissues, driving the malignant progression of tumors [8]. This process is tightly regulated by an exceptionally intricate molecular regulatory network, encompassing multiple levels including gene mutations, epigenetic modifications, transcription factor activation, dysregulation of signaling pathways, non-coding RNA regulation, and interactions within the tumor microenvironment [9]. Therefore, comprehensive and systematic elucidation of this regulatory network is critically important for understanding the biological behavior of HCC, developing metabolism-targeted therapeutic strategies, and identifying novel clinical biomarkers. This review will provide a detailed exposition of the molecular regulatory mechanisms underlying glycolytic reprogramming in HCC and its clinical relevance from multiple dimensions—including key glycolytic molecules, non-coding RNAs, classical signaling pathways, post-translational modifications, the tumor microenvironment, and clinical applications—based on the latest research advances. Multidimensional Regulation of Key Glycolytic Enzymes and Transporters Glycolysis is an enzymatic reaction cascade whose rate and directionality are strictly controlled by multiple key enzymes and substrate transporters. In hepatocellular carcinoma, the expression and activity of these molecules undergo multilevel, multidimensional regulation, collectively forming the basis of glycolytic reprogramming. Pyruvate Kinase M2 Isoform (PKM2): the Central Node Integrating Glycolysis and Biosynthesis Pyruvate Kinase (PK) catalyzes the final step of glycolysis, representing a critical rate-limiting reaction [10]. The PKM gene generates two isoforms, PKM1 and PKM2, through alternative splicing. PKM1 primarily exists as a highly active tetramer that efficiently catalyzes the conversion of phosphoenolpyruvate (PEP) to pyruvate, commonly found in normal differentiated tissues. In contrast, PKM2 predominates in tumor cells and proliferating cells, with its activity dynamically regulated between the highly active tetrameric form and the low-activity dimeric form. The low-activity PKM2 dimer slows the final step of glycolysis, causing accumulation of upstream glycolytic intermediates. These intermediates are subsequently diverted into biosynthetic pathways such as the pentose phosphate pathway (PPP), providing raw materials for cellular proliferation. Therefore, targeting PKM2 regulation represents the core of glycolytic reprogramming in tumors. Multiple mechanisms are involved in regulating PKM2. At the post-transcriptional modification level, RNA methylation modifications play a crucial role. For instance, the methyltransferase NSUN2 significantly enhances mRNA stability by performing m⁵C (5-methylcytosine) modifications on PKM2 mRNA. This upregulates PKM2 protein expression levels and promotes glycolysis in liver cancer cells [11]. Similarly, the RNA-binding protein HNRNPC, functioning as an ‘reader’ for m⁶A (N6-methyladenosine) modifications, recognizes and binds to m⁶A sites on PKM2 mRNA. This likewise upregulates PKM2 expression by enhancing mRNA stability, thereby driving glycolysis [12]. Protein-level interactions are also critically important. GTP-binding protein 4 (GTPBP4) was found to directly interact with PKM2, promoting its activity and thereby enhancing glycolysis and metastatic capabilities in liver cancer cells [13]. Heat shock protein 90 (HSP90), functioning as a molecular chaperone, upregulates PKM2 expression and facilitates the glycolytic process in liver cancer [14]. Furthermore, certain circular RNAs (circRNAs) can directly translate into small peptides that regulate PKM2. For example, circPETH encodes a polypeptide named PETH-147aa, which interacts with PKM2 to promote its activity and enhance glycolysis [15]. Conversely, inhibitory mechanisms targeting PKM2 also exist. lncRNA ORPH can inhibit PKM2 activity by functioning as a miR-491-5p sponge to indirectly upregulate downstream targets [16]. Certain viral proteins, such as the nucleocapsid protein (N protein) of SARS-CoV-2, can suppress PKM expression or function by modulating the RNA-binding protein YBX1 [17]. In thyroid cancer, the E3 ubiquitin ligase RBX1 has also been shown to promote tumor metastasis through regulating PKM2, indicating the universality of PKM2 regulatory mechanisms across different cancer types [18]. The natural compound Ailanthone has been found to directly bind PKM2, inhibiting its activity and consequently suppressing glycolysis in liver cancer, demonstrating potential therapeutic value [19]. Hexokinase (HK) and Phosphofructokinase (PFK): Initiation and Key Regulatory Points of Glycolysis Hexokinase (HK) catalyzes the first reaction of glycolysis, phosphorylating glucose to glucose-6-phosphate, an irreversible key step. Hexokinase 2 (HK2) serves as the predominant hexokinase isoform in tumors, and its elevated expression is a hallmark of enhanced glycolysis. Multiple non-coding RNAs participate in regulating HK. The long non-coding RNA TUG1 acts as a ‘molecular sponge’ for miR-455-3p, sequestering and inhibiting miR-455-3p. This action alleviates miR-455-3p’s suppression of downstream target genes AMPK β 2 and HK2, ultimately promoting glycolysis [20]. Conversely, certain miRNAs directly inhibit HK expression. For example, miR-139-5p has been demonstrated to simultaneously target and suppress the expression of both HK1 and another key glycolytic enzyme, 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3 (PFKFB3), thereby effectively inhibiting glycolysis in liver cancer cells [21]. In laryngeal cancer, miR-125b-5p also suppresses glycolysis by downregulating HK2 expression [22]. Phosphofructokinase (PFK) is one of the most critical rate-limiting enzymes in the glycolytic pathway, catalyzing the conversion of fructose-6-phosphate to fructose-1,6-bisphosphate. Its activity is regulated by multiple allosteric mechanisms. The deubiquitinating enzyme USP14 was found to upregulate PFK protein levels and promote glycolysis by stabilizing the liver isoform of phosphofructokinase (PFKL), thereby preventing its degradation [23]. The transcription factor CTCF directly upregulates expression of the deubiquitinase USP27, which in turn stabilizes the glycolytic enzyme PFKFB3 via deubiquitination. This hierarchical signaling cascade propels glycolytic reprogramming, fueling tumor growth and metastatic dissemination [24]. Complementing these pathways, the oncogenic long non-coding RNA FIRRE—frequently amplified in HCC and correlated with advanced staging and poor prognosis—orchestrates a distinct transcriptional circuit. FIRRE activates the transcription factor CREB, which subsequently induces expression of the key glycolytic enzyme PFKFB4, thereby reinforcing glycolytic flux and proliferation in HCC [25]. Recent studies have shown that METTL3 enhances the m6A modification of BFSP1 mRNA and increases its stability in a YTHDF1-dependent manner, thereby enabling the BFSP1–TMOD4 axis to drive aerobic glycolysis and malignant phenotypes in HCC cells [26] Moreover, suppression of APOM expression significantly elevates glucose uptake in liver cancer cells, accompanied by increased mRNA and protein levels of lactate dehydrogenase A (LDHA), as well as higher lactate and ATP production [27]. Glucose Transporter Proteins (GLUTs): the ‘Glucose Gates’ of Tumor Cells The prerequisite for high glycolysis in tumor cells is efficient glucose uptake from the extracellular environment, primarily dependent on the glucose transporter protein (GLUTs) family on the cell membrane. GLUT1 is the most prevalent and critically important glucose transporter protein commonly expressed in tumors. Multiple molecular pathways can upregulate GLUT1 expression. For example, the long non-coding RNA lnc-p23154 promotes GLUT1 expression, thereby enhancing glucose uptake and glycolysis in liver cancer cells [28]. The pyruvate dehydrogenase complex E2 subunit (DLAT) has also been found to upregulate GLUT1 expression, thereby promoting glycolysis and tumor metastasis [29]. Further studies reveal a positive feedback loop: long non-coding RNA SLC2A1-DT (the antisense transcript of GLUT1) forms a reciprocal regulatory circuit with transcription factor c-Myc, mutually enhancing each other’s expression to collectively drive glycolysis [30]. In head and neck squamous cell carcinoma, upregulated GLUT4 expression also correlates with metastasis [31]. Additionally, transcription factor S100A2 promotes glycolysis by activating HNF1A to upregulate GLUT2 expression [32], demonstrating synergistic effects among different GLUT family members in tumor glycolysis. Regulation of Other Key Enzymes Other enzymes in the glycolytic pathway are also subject to precise regulation. Phosphoglycerate mutase 1 (PGAM1), a key enzyme bridging the upper and lower glycolytic flux, has been shown to undergo transcriptional upregulation through direct binding of transcription factor RFX6 to its promoter region, thereby promoting glycolysis in hepatocellular carcinoma [33]. Downregulation of triosephosphate isomerase (TPI1) has also been implicated in enhanced glycolysis in liver cancer, likely mediated through its regulation of Rab20 protein [34]. In renal cell carcinoma, FKBP10 enhances lactate dehydrogenase A (LDHA) activity by promoting its phosphorylation, thereby driving tumor progression [35]. Conversely, certain molecules exert inhibitory effects. For instance, expression of glutaryl-CoA dehydrogenase (GCDH) suppresses glycolysis and exerts anti-tumor effects [36]. These observations underscore the complexity of glycolytic regulation and its central role in metabolic reprogramming in HCC. To provide a clearer synthesis of these molecular mechanisms, Table 1 summarizes the major molecular regulators identified to date and their corresponding targets within the anaerobic glycolytic pathway of hepatocellular carcinoma. Table 1Molecular preparations and their target sites of action on anaerobic Glycolysis in hepatocellular carcinomaAgentMechanismOutcome of HCCReference Girdin-KD Via PI3K/AKT/HIF-1α signaling pathwayInhibits glycolysis and enhances radiosensitivity in HepG2 and Huh-7 cells [37] LCN2-OE Upregulates JAK2 and STAT3 phosphorylationPromotes aerobic glycolysis and accelerates malignant proliferation [38] UCHL5-OE Activates Wnt/β-catenin pathwayPromotes glycolysis and HCC progression [39] Dectin3-OE Regulates macrophage glycolysisPromotes tumor cell apoptosis and inhibits proliferation [40] ZFP91-KD Regulates the PKM pre-mRNA through hnRNPA1toform higher PKM1 isoforms and supresses lower PKM2 isoformSuppresses proliferation, and metastasis [41] UQCC3-OE Sustains mtOXPHOS, HIF1a stabilization, and glycolytic activityMore progressive outcomes and shortened survival [42] Long non-coding RNA UPK1A-AS1-OE Stabilizes HIF-1α and upregulates glycolysis-related genesPromotes glycolysis in HCC cells [43] MAZ-OE Upregulates NEIL3-mediated aerobic glycolysisPromotes angiogenesis in HCC [44] KBTBD11-OE Promotes ENO1 degradationInhibits hepatocellular carcinoma [45] ZNF692-KD Stimulates glycolysis, proliferation, invasion, and migration in HepG2 cellsPromotes tumor progression [46] HSF2-OE Inhibits FBP1 expressionRegulates aerobic glycolysis in HCC [47] RFX6-OE Increases PGAM1 protein levelsPromotes HCC growth and metastasis via aerobic glycolysis [33] NPSR1-AS1-KD Downregulates MAPK/ERK pathwayInhibits HCC cell proliferation and glycolysis [48] CENPL-OE Activates MEK1/2-ERK1/2 signalingPromotes HCC cell proliferation and glycolysis [49] USP11-OE Induces glycolysis via HIF-1α/LDHAPromotes HCC proliferation and metastasis [50] NSUN5-OE Promotes glycolysis via m5C-EFNA3Accelerates HCC progression [51] MyD88-OE Promotes PERK-dependent PKM2 nuclear relocalization and activationDrives aerobic glycolysis-mediated hepatocarcinogenesis [52] miR-142-3p-OE Targets LDHAInhibits aerobic glycolysis and cell proliferation in HCC [53] miR-139-5p-OE Mutual regulation with ETS1Inhibits aerobic glycolysis, proliferation, migration, and invasion in HCC [21] MLXIPL-OE Promotes mTOR phosphorylationEnhances migration, invasion, and glycolysis in HCC cells [54] Molecular preparations and their target sites of action on anaerobic Glycolysis in hepatocellular carcinoma Central Role of Non-coding RNAs in Regulating Glycolysis in Liver Cancer Non-coding RNAs (ncRNAs) refer to RNA molecules lacking protein-coding function, once considered ‘dark matter’ within the genome. However, mounting evidence indicates that ncRNAs play crucial roles in regulating gene expression, forming complex regulatory networks. In the glycolytic reprogramming of hepatocellular carcinoma, lncRNAs, circRNAs, and miRNAs function as master regulators through diverse mechanisms. Long non-coding RNAs (lncRNAs) LncRNAs are a class of ncRNAs exceeding 200 nucleotides in length. They regulate gene expression through multiple mechanisms, such as acting as molecular sponges to sequester miRNAs, interacting with proteins to alter their functions, or directly modulating transcription [55]. Multiple lncRNAs have been identified as promoting factors for glycolysis in HCC. As previously mentioned, TUG1 promotes glycolysis by sponging miR-455-3p to indirectly upregulate HK2 expression [20]. Furthermore, TUG1 can be transmitted intercellularly via exosomes. Upon entering recipient cells, it upregulates the target gene SIX1 by sponging miR-524-5p, thereby promoting malignant progression of liver cancer [56]. Lnc-p23154 directly enhances the expression of the key glucose transporter protein GLUT1 [28]. The long non-coding RNA CYTOR interacts with the RNA-binding protein HNRNPC to enhance HNRNPC-mediated stabilization of downstream target gene ZEB1 mRNA. ZEB1 serves as a critical transcription factor promoting both epithelial-mesenchymal transition (EMT) and glycolysis [57]. MALAT1 is another well-known oncogenic lncRNA that upregulates the expression of transcription factor TCF7L2 in liver cancer, thereby promoting glycolytic reprogramming [58]. LINC01123 has also been confirmed to promote the proliferation and metastasis of liver cancer cells, and its mechanism may also be related to metabolic regulation [59]. Circular RNAs (circRNAs) CircRNAs are a class of ncRNAs with closed circular structures that have become a research hotspot in recent years due to their high stability and strong tissue specificity. They exhibit dual regulatory roles in HCC glycolysis. On one hand, certain circRNAs promote glycolysis. For instance, circPETH activates PKM2 through its encoded small peptide PETH-147aa, thereby promoting glycolysis [15]. CircC16orf62 functions as a sponge for miR-138-5p, relieving its inhibitory effect on the downstream target gene PTK2, consequently facilitating liver cancer progression [60]. On the other hand, other circRNAs act as suppressors of glycolysis. In hepatocellular carcinoma, circRPN2 significantly suppresses cellular glycolytic activity and metastatic potential [61]. In nasopharyngeal carcinoma, circRNF13 exerts inhibitory effects on glycolysis by regulating SUMO2 protein, suggesting that circRNAs may regulate metabolism through similar or distinct mechanisms across different tumors [62]. MicroRNAs (miRNAs) MiRNAs are short-chain ncRNAs approximately 22 nucleotides in length. They primarily bind to the 3’-untranslated region (3’-UTR) of target mRNA, leading to mRNA degradation or translational repression, thereby precisely regulating gene expression at the post-transcriptional level. In HCC glycolytic regulation, the miRNA network plays a fine-tuned regulatory role. Some miRNAs act as direct inhibitors of glycolysis. For instance, miR-139-5p can simultaneously target and downregulate the expression of two key glycolytic enzymes, HK1 and PFKFB3 [21]. miR-3662 indirectly suppresses the entire HIF-1α-driven glycolytic program by inhibiting hypoxia-inducible factor-1α (HIF-1α) expression [63]. Deficiency of mineralocorticoid receptor (MR) promotes glycolysis through downregulation of miR-338-3p, leading to upregulation of its target genes [64]. Similar inhibitory miRNAs have been identified in other tumors including laryngeal carcinoma and nasopharyngeal carcinoma, such as miR-125b-5p which suppresses glycolysis in laryngeal carcinoma by downregulating HK2 [22]. Meanwhile, numerous miRNAs function as intermediary components within signaling pathways, regulated by upstream lncRNAs or circRNAs. As exemplified by the TUG1/miR-455-3p/HK2 axis [20], TUG1/miR-524-5p/SIX1 axis [56], and ORPH/miR-491-5p/PKM2 axis [16], these cases clearly demonstrate the complexity and significance of competitive endogenous RNA (ceRNA) networks in regulating glycolysis [65]. Networked Regulation of Classical Signaling Pathways and Transcription Factors Cellular metabolic status is tightly regulated by multiple signaling pathways that perceive intra- and extracellular environmental changes, ultimately influencing the transcription of metabolism-related genes and enzyme activity through cascade reactions. In hepatocellular carcinoma, aberrant activation of multiple classical signaling pathways serves as the primary driver of glycolytic reprogramming. PI3K/Akt/mTOR Pathway: the Central Hub Regulating Growth and Metabolism The PI3K/Akt/mTOR signaling pathway constitutes a core regulatory network governing cell growth, proliferation, survival, and metabolism [66]. In HCC, this pathway frequently exhibits sustained activation due to hyperactivation of upstream receptor tyrosine kinases (RTKs) or mutations in key pathway components [67]. Activated Akt promotes glycolysis through multiple mechanisms: it facilitates GLUT1 translocation to the cell membrane, enhancing glucose uptake; can phosphorylate and activate PFKFB2, elevating levels of fructose-2,6-bisphosphate—an allosteric activator of glycolysis further promotes the translation of pro-glycolytic transcription factors such as HIF-1 α and c-Myc through mTORC1 activation. Multiple studies have confirmed the central role of this pathway in HCC glycolysis. VersicanV1, a proteoglycan in the tumor microenvironment, significantly enhances glycolysis in liver cancer cells by activating the EGFR-PI3K-AKT signaling pathway [68]. In renal cell carcinoma, DEPDC1 protein drives glycolysis by activating the AKT/mTOR/HIF1α axis [69]. The fatty acid transporter CD36 also promotes glycolysis through activation of the Src/PI3K/AKT signaling pathway [70]. Furthermore, activation of the PI3K/Akt signaling pathway not only enhances glycolysis in liver cancer but also closely correlates with tumor chemoresistance [71]. AMPK Signaling Pathway: the ‘Sensor’ of Cellular Energy Status AMP-activated protein kinase (AMPK) serves as an intracellular energy sensor. When the AMP/ATP ratio increases (indicating energy deficiency), AMPK is activated and restores energy balance by inhibiting anabolism while promoting catabolism [72]. Under normal physiological conditions, AMPK activation typically suppresses glycolysis. However, in tumors, the role of AMPK is more complex. Some studies indicate that inhibiting the AMPK pathway facilitates tumor glycolysis. For instance, histone deacetylase HDAC11 suppresses LKB1 (an upstream kinase), thereby inhibiting AMPK activity [73]. This mechanism relieves AMPK-mediated suppression of glycolysis and promotes tumor growth [74]. Nevertheless, other research suggests that under certain circumstances, tumor cells may hijack the AMPK pathway to enhance survival. The TUG1/miR-455-3p axis promotes glycolysis by upregulating AMPK β 2 [20]. Inhibitors of GSK-3 β suppress glycolysis in liver cancer via the AMPK/mTOR pathway, demonstrating complex crosstalk between these signaling pathways [75]. Wnt/β-catenin Pathway and c-Myc: A Key Axis Driving Proliferation and Metabolism The Wnt/ β-catenin signaling pathway plays a critical role in embryonic development and tissue homeostasis. Its aberrant activation represents one of the most common molecular events in HCC [76]. The core component of this pathway is the β-catenin protein. Upon pathway activation, stabilized β-catenin accumulates in the cytoplasm and translocates to the nucleus, where it binds to transcription factors of the TCF/LEF family to initiate transcription of downstream target genes, including the well-known proto-oncogene c-Myc [77]. c-Myc, a potent transcription factor, serves as the central engine driving the Warburg effect by systemically upregulating the expression of nearly all glycolytic pathway genes, including GLUT1, HK2, PFK, and LDHA. Gankyrin, an oncoprotein highly expressed in liver cancer, has been shown to promote glycolysis by activating the β-catenin/c-Myc axis [78]. Phosphoglycerate kinase 1 (PGK1) can also activate the β-catenin/c-Myc pathway through interaction with MYH9, thereby promoting glycolysis [79]. Conversely, Casein Kinase I (CKI) exerts inhibitory effects on HCC glycolytic metabolism by suppressing the β-catenin/c-Myc pathway [80]. HIF-1α: the Glycolytic Switch Under Hypoxic and Normoxic Conditions Hypoxia-Inducible Factor-1α (HIF-1α) serves as a pivotal transcription factor enabling cellular adaptation to low-oxygen environments. Under hypoxia, the HIF-1α protein stabilizes and translocates into the nucleus, initiating the transcription of a series of target genes that promote cellular survival in low oxygen. Crucially, this includes nearly all genes associated with glycolysis. Within solid tumors, abnormal angiogenesis often leads to extensive hypoxic regions. In these areas, activation of HIF-1 α is crucial for cell survival and maintenance of high glycolysis levels. However, in tumors, activation of HIF-1 α is not entirely dependent on hypoxia. Accumulation of numerous oncogenic signaling pathways and metabolites can stabilize HIF-1 α even under normoxic conditions. For instance, deletions of fumarate hydratase (FH) or the VHL tumor suppressor gene—commonly found in hereditary renal cell carcinoma—both lead to stabilization of HIF-1 α and significant enhancement of glycolysis [81–83]. Inactivation of TET2 can also promote the progression of VHL-deficient renal cancer by stabilizing the HIF signaling pathway [84]. Conversely, inhibiting HIF-1 α through pharmacological or genetic approaches, such as direct suppression by miR-3662, effectively suppresses glycolysis [63]. Viral Oncoproteins in HCC: Coordinating Glycolytic and Biosynthetic Pathways Key proteins of hepatitis B virus (HBV) and hepatitis C virus (HCV) play a central role in inducing glycolytic phenotypes and regulating metabolism upon infection of hepatocytes, representing a critical mechanism in virus-associated hepatocellular carcinoma (HCC) development [85]. The HBV X protein (HBx) directly interacts with liver X receptor α (LXRα), enhancing its transcriptional activation function, which upregulates genes involved in lipid biosynthesis and promotes lipogenic pathways. Concurrently, HBx disrupts mitochondrial function and perturbs cellular redox balance, rendering tumor cells more dependent on glycolysis for energy production. In addition, HBx activates multiple classical pro-survival signaling pathways, including MAPK and PI3K-AKT, whose downstream effects often involve upregulation of key glycolytic enzymes such as glucose transporters (GLUTs) and hexokinase 2 (HK2), further augmenting glycolytic flux. Complementarily, the HBV core antigen (HBcAg) interacts with the MLX transcription factor to activate glycolysis-related gene expression; HBcAg also engages with multiple key enzymes in glycine and phenylalanine metabolism (e.g., glycine N-methyltransferase and 4-hydroxyphenylpyruvate dioxygenase), thereby stimulating these metabolic branches. Consequently, the metabolic reprogramming mediated by HBcAg—manifested as enhanced glycolysis and fatty acid synthesis—is recognized as a hallmark of viral oncogenesis. In addition to HBV proteins, HCV NS5A directly interacts with hexokinase 2 (HK2), enhancing its enzymatic activity and thereby increasing glucose consumption and lactate production [86]. Moreover, HCV protein expression induces mitochondrial dysfunction and oxidative stress, leading to HIF-1α stabilization and upregulation of glycolytic genes [87]. HBV exploits hexokinase 2 (HK2) and glycolysis-derived lactate to suppress RIG-I–MAVS signaling, thereby facilitating viral immune evasion while simultaneously driving glycolytic reprogramming in hepatocytes [88]. HBV activates nicotinamide phosphoribosyltransferase (NAMPT) via the DNA damage sensor ATR, and NAMPT–insulin receptor (INSR)-mediated hepatocyte–HSC signaling drives HSC transdifferentiation into myofibroblasts and PARP1-dependent multisite lactylation of telomere maintenance components, while targeting the ATR–NAMPT–INSR–PARP1 axis effectively attenuates HBV-induced liver fibrosis and HCC progression [89]. Post-translational Modifications and their Relevance To HCC In addition to transcriptional and translational regulation, post-translational modifications (PTMs) of key glycolytic enzymes play a critical role in the dynamic modulation of glycolytic pathways in HCC [90]. These modifications, including phosphorylation, acetylation, methylation, and more recently discovered lactylation, are essential in fine-tuning enzyme activity and ensuring metabolic flexibility, particularly in tumor cells that exhibit altered metabolic reprogramming. Figure 1 illustrates the comprehensive molecular regulatory network underlying glycolytic reprogramming in HCC Below, we highlight some of the key PTMs involved in glycolytic reprogramming in HCC and their functional implications. Molecular regulatory network of glycolytic reprogramming in HCC. This figure provides an integrated overview of the key regulatory axes driving glycolytic reprogramming in HCC, encompassing critical glycolytic enzymes, non-coding RNAs, classical signaling pathways, and diverse post-translational modifications. It further highlights the modulatory influence of various cellular components within the tumor microenvironment. Together, these multilayered regulatory mechanisms orchestrate a metabolic phenotype marked by enhanced glycolytic activity Phosphorylation and Acetylation of PKM2 PKM2, a central enzyme in glycolysis, is known for its dual form: the highly active tetramer and the less active dimer. The regulation of PKM2’s activity is tightly controlled by post-translational modifications, which include phosphorylation and acetylation. Studies have shown that PKM2 predominantly exists in its less active dimeric form in tumor cells, allowing for the accumulation of glycolytic intermediates that can be redirected into anabolic pathways. For instance, phosphorylation of PKM2 at specific sites can stabilize the dimeric form and prevent its transition to the more active tetrameric form [91]. Additionally, acetylation of PKM2 can modulate its enzymatic activity, influencing glycolytic flux and tumor progression. These PTMs allow PKM2 to act as a key node in both metabolic and biosynthetic networks that sustain cancer cell growth and survival. RNA Methylation and mRNA Stability of PKM2 Beyond direct modifications of PKM2 protein, its mRNA stability is regulated by RNA methylation. The m5C methyltransferase NSUN2 enhances the stability of PKM2 mRNA through m5C modifications, thus promoting the expression of PKM2 in liver cancer cells [11]. This methylation process is critical for maintaining glycolytic activity and tumor metabolism0916. Furthermore, RNA-binding proteins such as HNRNPC interact with methylated PKM2 mRNA, stabilizing it and supporting the sustained production of PKM2 protein, even in the presence of cellular stress [92]. This regulation at the mRNA level further integrates post-transcriptional control in metabolic reprogramming. Ubiquitination and SUMOylation of PKM2 In addition to phosphorylation and acetylation, ubiquitination and SUMOylation of PKM2 also influence its stability and function in HCC [93]. Ubiquitin-specific protease 14 (USP14) has been shown to deubiquitinate PFKL [94], stabilizing the enzyme and promoting glycolysis. Similarly, SUMOylation, a modification where small ubiquitin-like modifiers (SUMOs) are attached to proteins, has been implicated in regulating PKM2 stability and activity [95]. SUMOylation of PKM2 plays a role in maintaining glycolytic flux under conditions of metabolic stress and contributes to the aggressive behavior of HCC cells. Acetylation of Hexokinase 2 (HK2) HK2 is another key glycolytic enzyme frequently overexpressed in tumor cells [96]. In HCC, acetylation of HK2 enhances its stability and function, facilitating glucose phosphorylation and enabling the tumor to meet its increased energy demands. Specifically, acetylation prevents HK2 from being degraded by the proteasome, thereby supporting persistent glycolytic activity, even in hypoxic conditions. Lactylation as a Novel PTM in HCC Lactylation, a relatively novel histone modification, has emerged as a significant PTM that links glycolytic activity to epigenetic regulation. This modification involves the attachment of a lactate-derived lactyl group to lysine residues on histones, which can alter chromatin structure and gene expression [97]. In HCC, lactate, a byproduct of glycolysis, can directly promote lactylation of histones, activating genes associated with inflammation, immune evasion, and tumor repair [98]. The lactylation of histones also promotes a pro-tumorigenic immune microenvironment by modulating macrophage polarization, further enhancing tumor growth and metastasis [99]. Tumor Microenvironment and Intercellular Communication Remodel Glycolytic Metabolism in Liver Cancer Tumors are not composed solely of cancer cells but constitute complex ecosystems known as the tumor microenvironment (TME). The TME encompasses diverse non-tumor cellular components—including immune cells, fibroblasts, and vascular endothelial cells—alongside the extracellular matrix and various soluble factors. These components engage in close interactions and exhibit metabolic symbiosis with tumor cells, collectively influencing the tumor’s glycolytic status and malignant progression. Regulation of HCC Glycolysis by Microenvironmental Cells Tumor-associated macrophages (TAMs) constitute one of the most abundant immune cell populations in the TME, typically displaying an M2-like phenotype that promotes tumor growth. In HCC, TAMs can modulate tumor cell metabolism through multiple mechanisms. Research indicates that expression of carbonic anhydrase XII (CA12) in TAMs enhances glycolytic activity in HCC [100]. Furthermore, derivatives of glutamine can enhance glycolysis within TAMs themselves, enabling better adaptation to the acidic microenvironment and facilitating their pro-tumorigenic functions [101]. Hepatic stellate cells (HSCs), liver-specific mesenchymal cells, play a pivotal role in liver fibrosis and liver cancer development. The acidic microenvironment created by lactate produced through glycolysis activates HSCs. In turn, activated HSCs secrete various growth factors and cytokines that promote HCC invasion and metastasis [5]. Mediating Role of Extracellular Vesicles and Soluble Factors Intercellular communication serves as the cornerstone of information exchange within the TME [102]. Extracellular vesicles (EVs), particularly small extracellular vesicles (sEVs, i.e., exosomes), function as crucial information carriers capable of transmitting proteins, lipids, and nucleic acids between cells, thereby regulating recipient cell functions [103]. Studies reveal that sEVs containing nicotinamide phosphoribosyltransferase (NAMPT) secreted by liver cancer cells can promote glycolysis in recipient cells by targeting the fatty acid transporter SLC27A4 [104]. As noted earlier, exosomes containing lncRNA TUG1 can also transmit pro-tumorigenic signals between cells [56]. Soluble macromolecules within the extracellular matrix also participate in metabolic regulation. The versican V1 isoform of proteoglycans has been found to promote HCC glycolysis by activating the EGFR-PI3K-AKT pathway [68]. Neutrophil extracellular traps (NETs), a web-like structure released by neutrophils, have also been demonstrated to facilitate tumor metastasis [105], a mechanism likely also linked to alterations in tumor cell metabolic states. Importantly, many of the above microenvironmental cues converge on O-GlcNAcylation, a nutrient-sensing post-translational modification tightly coupled to glucose and glutamine metabolism. Serving as a central biochemical interface, O-GlcNAc cycling integrates inflammatory mediators, EV-derived cargoes, and matrix-associated factors to fine-tune glycolytic enzyme activities and oncogenic signaling pathways. To further elucidate these regulatory interactions, Table 2 summarizes key molecules that regulate or are regulated by O-GlcNAcylation in hepatocellular carcinoma, highlighting their roles in tumor progression and metabolic reprogramming. Table 2Molecules regulating or regulated by O-GlcNAcylation in HCCMoleculeSiteFunctionReference PGRN Thr272Activates PI3K/AKT/mTOR signaling to drive HCC cell proliferation [106] RACK1 Ser122Enhances RACK1 stability and ribosomal localization, facilitating PKCβII interaction and oncogenic translation in HCC [107] SIX1 Thr276O-GlcNAcylation at Thr276 stabilizes SIX1 and promotes HCC proliferation [108] EIF4E Thr168/Thr177Promotes stem cell–like phenotypes in liver cancer cells [109] TFRC Ser687Regulates ferroptosis in HCC [110] SPOP Ser96Increases nuclear SPOP localization, reduces Nogo-B ubiquitination, and promotes HCC progression [111] RALY Ser176Enhances RALY interaction with USP22 mRNA to promote HCC cell proliferation [112] METTL3 Thr186/Ser192/Ser193Increases METTL3 stability and promotes HCC progression [113] CHK2 Thr378Enhances CHK2 kinase activity and promotes hepatocarcinogenesis [114] PKM2 Thr405/Ser409Regulates metabolic and non-metabolic PKM2 functions, enhancing the Warburg effect and tumor proliferation [115] VEZF1 Ser123/Ser124O-GlcNAcylation enhances VEZF1-mediated proliferation and migration in HCC [116] FOXK2 Ser424Enhances cystine uptake and inhibits tumor cell death in HCC [117] YBX1 Thr57Promotes transcription of glycolytic genes and stabilizes PKM2 mRNA, facilitating HCC proliferation [118] Molecules regulating or regulated by O-GlcNAcylation in HCC Glycolytic Activity as Biomarkers for Liver Cancer Diagnosis and Prognostic Evaluation Given the central role of glycolysis in tumor biology, detecting tumor glycolytic activity has become a crucial clinical tool. 18 F-fluorodeoxyglucose positron emission tomography/computed tomography (18 F-FDG PET/CT) currently represents the most widely used non-invasive imaging technique for assessing in vivo glycolytic activity in clinical practice. This technique operates on the principle of exploiting the high glucose uptake characteristic of tumor cells. By detecting the accumulation of the radioactive glucose analog 18 F-FDG in tumor tissues, it quantifies the metabolic activity of tumors [119]. Multiple PET/CT-derived metabolic parameters serve to evaluate tumor aggressiveness and prognosis [120–122]. Maximum Standardized Uptake Value (SUVmax) indicates the peak metabolic activity within tumor regions. Metabolic Tumor Volume (MTV) quantifies the total volume of tumor tissue exhibiting elevated FDG uptake. Total Lesion Glycolysis (TLG), calculated as the product of MTV and mean SUV, comprehensively reflects both the total tumor burden and average metabolic activity. Substantial clinical evidence confirms these metabolic parameters as robust predictors of prognosis in HCC and diverse other malignancies. A study on HCC revealed that preoperative MTV and TLG serve as independent risk factors for predicting postoperative metastatic recurrence in patients [123]. Tumors exhibiting such high metabolic activity often demonstrate greater aggressiveness and poorer prognosis. This finding has been validated across multiple other tumor types. For instance, in renal cell carcinoma (RCC), MTV and TLG have been established as significant predictors of patient prognosis [123]. In oral cavity cancer, preoperative PET/CT-derived MTV and TLG values can predict the risk of occult cervical lymph node metastasis [124]. In nasopharyngeal carcinoma, TLG is considered an independent prognostic factor for predicting patient survival [125, 126]. In endometrial cancer, MTV and TLG also contribute to risk stratification of patients [127]. Collectively, these studies highlight the enormous potential of glycolytic activity as a functional biomarker in clinical staging, treatment decision-making, and prognosis assessment of tumors. Conclusion Glycolytic reprogramming in hepatocellular carcinoma represents not merely an isolated metabolic event, but a precisely regulated process—collectively intertwined by genetic, epigenetic, signal transduction, and microenvironmental factors—that is multi-layered and networked in nature. This systematic review reveals that the core regulatory function of this complex network lies in ensuring tumor cells continuously and efficiently uptake glucose, preferentially channeling it into the glycolytic pathway to meet their dual demands for energy supply and biosynthesis (Fig. 2). Schematic of “glycolytic reprogramming” in HCC. Glucose enters via GLUT and is sequentially catalyzed by HK2, GAPDH, PKM2, etc., yielding lactate exported by up-regulated LDHA. While pyruvate can enter mitochondria for TCA/OXPHOS, this route is blocked under hypoxia or oncogenic signaling, boosting lactate output. PI3K/Akt/mTOR, HIF-1α and c-Myc up-regulate glycolytic genes. AMPK suppression further impairs mitochondrial oxidation. ncRNAs fine-tune enzyme levels, and lactate accumulation promotes immune escape and tumor progression At the molecular level, key nodes in the glycolytic pathway—particularly PKM2, HK2, and GLUT1—are intensively regulated through multiple dimensions. Non-coding RNAs, including lncRNAs, circRNAs, and miRNAs, constitute a crucial regulatory layer. Functioning as molecular sponges, modulating protein activity, or directly encoding functional polypeptides, they act like ‘precision-guided missiles’ to fine-tune or remodel glycolytic genes. Classical oncogenic signaling pathways, such as PI3K/Akt/mTOR and Wnt/β-catenin, function as upstream ‘supreme commands’ that integrate signals from growth factors and intracellular sources. They systematically initiate the entire glycolytic gene expression program by activating key transcriptional ‘executives’ such as HIF-1α and c-Myc. More intricately, post-translational modifications—including phosphorylation, acetylation, ubiquitination, and the newly discovered lactylation—act like real-time fine-tuning of machine components. These modifications dynamically regulate the activity and stability of glycolytic enzymes, enabling metabolic flux to rapidly adapt to cellular state changes. Furthermore, tumor cells do not operate in a vacuum. Within the tumor microenvironment, stromal cells, immune cells, and the cytokines and extracellular vesicles they secrete form a complex network of metabolic symbiosis and communication with tumor cells, collectively shaping a ‘metabolic ecosystem’ conducive to tumor growth. Ultimately, this cascade of intricate molecular events manifests macroscopically as high glucose uptake by tumor tissue. This phenomenon makes 18 F-FDG PET/CT-based metabolic imaging a powerful clinical tool for assessing tumor aggressiveness and predicting patient prognosis. In summary, a comprehensive understanding of the glycolytic regulatory network in HCC not only reveals the fundamental strategies underpinning tumor cell survival and progression, but also provides a solid theoretical foundation for identifying potential therapeutic targets and developing more precise clinical diagnosis and treatment approaches. Acknowledgements The authors thank Figdraw for providing diagram creation support. The figures were created with Figdraw (IDs: PTPRAd748c, TPWSI26779). Authors’ contributions writing—review and editing and funding acquisition, H.Z.; writing—review and editing, J.L.; writing—review and editing, J.Z.; writing—review and editing, D.N.; writing—review and editing, W.Z.; funding acquisition, C.J. All authors have read and agreed to the published version of the manuscript. Funding This study was financially supported by the National Natural Science Foundation of China No: 82304936, 82274269. The project also supported by the Top Talent Support Program for young and middle-aged people of Wuxi Health Committee (HB2023069, BJ2023064). Data availability No datasets were generated or analysed during the current study. Declarations Ethics approval and consent to participate Not applicable. Consent for Publication Not applicable. Competing Interests The authors declare no competing interests. Footnotes Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Hengzhou Zhu and Jiahui Li contributed equally to this paper. Contributor Information Weiwang Zheng, Email: 55170681@qq.com. Chunhui Jin, Email: wxzy013@njucm.edu.cn. References Associated Data Data Availability Statement No datasets were generated or analysed during the current study.